Better Buy: Gilead Sciences vs. Pfizer
Two healthcare giants have been at the forefront in the fight against COVID-19. Gilead Sciences (NASDAQ: GILD) was among the first companies to win FDA emergency use authorization (EUA) for an antiviral therapy targeting SARS-CoV-2, the novel coronavirus that causes COVID-19. Pfizer (NYSE: PFE) hopes to soon win the first EUA for a coronavirus vaccine.
You might think that Gilead and Pfizer would have delivered tremendous stock returns this year with their respective COVID programs racking up successes. That hasn't been the case, though, with both stocks in negative territory year to date.
Which of these two drug stocks is the better pick going forward? Here's how Gilead and Pfizer stack up against each other in several key areas.
Source Fool.com
